康德萊(603987.SH):康德萊醫械明起在聯交所主板上市交易
格隆匯11月7日丨康德萊(603987.SH)公佈,公司下屬控股子公司上海康德萊醫療器械股份有限公司(“康德萊醫械”)已向香港聯交所主板遞交公開發行H股股票及上市申請並獲香港聯交所批准。
此次康德萊醫械共發行4000萬股H股(未包括行使超額配股權後的股份),發行完成後康德萊醫械總股本增加至16000萬股,公司持有康德萊醫械內資股4285.7142萬股,佔康德萊醫械發行完成後總股本的26.79%。康德萊醫械的股票自2019年11月8日起在香港聯交所主板上市交易,股票代碼為“1501”,股票簡稱為“康德萊醫械”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.